Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2016, vol. 25, nr 5, September-October, p. 815–820

doi: 10.17219/acem/36459

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Effects of Propofol on the Liver Oxidative-Antioxidant Balance in a Rat Model of Parkinson’s Disease

Ewa B. Romuk1,B,C,D, Wioletta Szczurek1,C,D, Przemysław G. Nowak2,A,B,E,F, Edyta Hudziec1,B,C, Ewa Chwalińska1,B, Ewa Birkner1,E,F

1 Department of Biochemistry, Medical University of Silesia, Zabrze, Poland

2 Department of Toxicology and Addiction, Medical University of Silesia, Zabrze, Poland

Abstract

Background. Parkinson’s disease is caused by the destruction of dopaminergic neurons in the substantia nigra of the midbrain. One of the possible factors involved in the pathogenesis of Parkinson’s disease is impaired oxidativeantioxidative balance.
Objectives. The present study aimed to evaluate selected parameters of the liver oxidative-antioxidative system in a Wistar rat model with Parkinson’s disease treated with propofol.
Material and Methods. Experiments were performed on 32 rats divided into 4 groups: 1 – control, 2 – Parkinson’s disease, 3 – control with propofol, 4 – Parkinson’s disease with propofol. The rats were decapitated at 8 weeks of age and their livers were collected. In the liver, the activities of catalase (CAT), glutathione peroxidase (GPx), glutathione transferase (GST), glutathione reductase (GR) and the concentrations of: Malondialdehyde (MDA), total antioxidant capacity (TAC), total oxidant status (TOS) were assessed.
Results. The study demonstrated a decrease in CAT activity and an increase in MDA, TOS concentrations in group 2 compared to that of group 1. Administration of propofol in rats of group 4 caused an increase in CAT activity and a decrease in MDA concentration compared to that of group 2 and an increase in TAC, CAT, GR levels, decrease in MDA levels compared to that of group 1. There was also an increase in GR and TAC in group 3 compared to that of group 1.
Conclusion. Propofol in Parkinson’s disease stimulates the production of antioxidant enzymes in the liver, simultaneously decreasing oxidative stress, which has a beneficial effect on the oxidative-antioxidative balance.

Key words

oxidative stress, rats, Parkinson’s disease, propofol, antioxidant effects

References (30)

  1. Caudle WM, Guillot TS, Lazo CR, Miller GW: Industrial toxicants and Parkinson’s disease. Neurotoxicology 2012, 33, 178–188.
  2. Nowak P, Szczerbak G, Dąbrowska J, Bortel A, Biedka I, Kostrzewa RM: Molecular mechanisms of levodopa action in animal models of Parkinson’s disease. Neurol Neurochir Pol 2006, 40, 517–525.
  3. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G: Peripheral blood markers of oxidative stress in Parkinson’s disease. Eur Neurol 2007, 58, 78–83.
  4. Shukla V, Mishra SK, Pant HC: Oxidative stress in neurodegeneration. Adv Pharmacol Sci 2011, 572634. DOI: 10.1155/2011/572634.
  5. Vanlersberghe C, Camu F: Propofol. Handb Exp Pharmacol 2008, 182, 227–252.
  6. Sokołowska D, Wendorff J: Role of free radicals in pathogenesis of neurodegenerative diseases. Stud Med 2009, 16, 49–53.
  7. Dauer W, Przedborski S: Parkinson’s disease: Mechanisms and models. Neuron 2003, 39, 889–909.
  8. Aebi H: Catalase in vitro. Methods Enzymol 1984, 105, 121–126.
  9. Richterich R: Chemia kliniczna. PZWL, Warszawa 1971.
  10. Paglia DE, Valentine WN: Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967, 70, 158–169.
  11. Habig WH, Jakoby WB: Assays for differentiation of glutathione S-transferases. Methods Enzymol 1981, 77, 398–405.
  12. Erel O: A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 2004, 37, 277–285.
  13. Erel O: A new automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38, 1103–1111.
  14. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979, 95, 351–358.
  15. Lowry OH, Rosebrough NJ, Farr AL, Randal RJ: Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193, 265–275.
  16. Fahn S, Cohen G: The oxidant stress hypothesis in Parkinson’s disease: Evidence supporting it. Ann Neurol 1992, 32, 804–812.
  17. Shichiri M: The role of lipid peroxidation in neurological disorders. J Clin Biochem Nutr 2014, 54, 151–160.
  18. Gaweł S, Wardas M, Niedworok, Wardas P: Malondialdehyde (MDA) as a lipid peroxidation marker. Wiad Lek 2004, 57, 453–455.
  19. Buhmann C, Arlt S, Kontush A, Möller-Bertram T, Sperber S, Oechsner M, Stuerenburg HJ, Beisiegel U: Plasma and CSF markers of oxidative stress are increased in Parkinson’s disease and influenced by antiparkinsonian medication. Neurobiol Dis 2004, 15, 160–170.
  20. Kirbas A, Kirbas S, Cure MC, Tufekci A: Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with idiopathic Parkinson’s disease. J Clin Neurosci 2014, 21, 451–455.
  21. Karpińska A, Gromadzka G: Oxidative stress and natural antioxidant mechanisms: The role in neurodegeneration. From molecular mechanisms to therapeutic strategies. Postepy Hig Med Dosw 2013, 67, 43–53.
  22. Ranjbar A, Sharifzadeh M, Karimi J, Tavilani H, Baeeri M, Heidary Shayesteh T, Abdollahi M: Propofol attenuates toxic oxidative stress by ccl4 in liver mitochondria and blood in rat. Iran J Pharm Res 2014, 13, 253–262.
  23. Wang H, Xue Z, Wang Q, Feng X, Shen Z: Propofol protects hepatic L02 cells from hydrogen peroxide-induced apoptosis via activation of extracellular signal-regulated kinases pathway. Anesth Analg 2008, 107, 534–540.
  24. Strathearn KE, Yousef GG, Grace MH, Roy SL, Tambe MA, Ferruzzi MG, Wu QL, Simon JE, Lila MA, Rochet JC: Neuroprotective effects of anthocyaninand proanthocyanidin-rich extracts in cellular models of Parkinson’s disease. Brain Res 2014, 1555, 60–77.
  25. Sikorska M, Lanthier P, Miller H, Beyers M, Sodja C, Zurakowski B, Gangaraju S, Pandey S, Sandhu JK: Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine model: Potential use as an adjuvant treatment in Parkinson’s disease. Neurobiol Aging 2014, 35, 2329–2346.
  26. Miyake Y, Fukushima W, Tanaka K, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M: Dietary intake of antioxidant vitamins and risk of Parkinson’s disease: A case-control study in Japan. Eur J Neurol 2011, 18, 106–113.
  27. Weber CA, Ernst ME: Antioxidants, supplements, and Parkinson’s disease. Ann Pharmacother 2006, 40, 935–938.
  28. Etminan M, Gill SS, Samii A: Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: A meta-analysis. Lancet Neurol 2005, 4, 362–365.
  29. Łukaszewicz-Hussain A: The role of glutathione and glutathione-related enzymes in antioxidative process. Med Pr 2003, 54, 473–479.
  30. Adaramoye OA, Akinwonmi O, Akanni O: Effects of propofol, a sedative-hypnotic drug, on the lipid profile, antioxidant indices, and cardiovascular marker enzymes in wistar rats. ISRN Pharmacol 2013, 230261. DOI: 10.1155/2013/230261.
© Wroclaw Medical University